# Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer

> **NCT03971045** · PHASE2 · RECRUITING · sponsor: **European Institute of Oncology** · enrollment: 46 (estimated)

## Conditions studied

- Breast Cancer
- Chest Wall Tumor

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03971045
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-20
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971045, "Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03971045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*